We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

A New Image for Cell Sorting Introduced

By LabMedica International staff writers
Posted on 10 May 2022
Print article
Image: Schematic of image-enabled cell sorting method, the BD CellView Image Technology (Photo courtesy of BD Biosciences)
Image: Schematic of image-enabled cell sorting method, the BD CellView Image Technology (Photo courtesy of BD Biosciences)

Methods that physically separate cells of interest on the basis of measurable characteristics have numerous uses in clinical studies and applications, including cellular therapies. Cells can also be sorted on the basis of signals from extrinsic probes.

Fluorescence-activated cell sorting (FACS) is the most popular means of separating a population of cells into subsets according to the total amount of key biomarkers that are expressed by each cell. These biomarkers are typically detected with fluorochrome-labeled antibodies.

Flow cytometry specialists from Newcastle University (Newcastle upon Tyne, UK) and the Broad Institute (Cambridge, MA, USA) have reviewed the latest advances in the use of FACS. The prototype instrument for this new means of sorting is an adaptation of the BD FACSMelody cell sorter (BD Biosciences, San Jose, CA, USA), which is considered the workhorse of FACS.

The new method, called BD CellView Image Technology, combined ultrafast microscopy and image analysis with a flow cytometric cell sorter to unlock spatial phenotypes for high-throughput sorting applications. Although this prototype instrument has only a few fluorescence channels (complex FACS systems have many more), it sorts cells according to the spatial pattern of fluorescence within each cell. The system relies on fast fluorescence imaging that uses radiofrequency-tagged emission and specialized low-latency signal processing and sorting electronics, a clever approach that provides spatial information for each signal.

The sorter physically separated the cells that had nuclear expression of RelA after nine hours of run time at a sorting rate of 14 million cells per hour. The investigators could then identify specific loci, the ablation of which blocked the nuclear translocation of RelA. They did this by sequencing unique guide RNAs that served as barcodes in the affected cells Overall, it appears that this system can aptly sort cells on the basis of prespecified complex morphologic characteristics.

Image-based cell-sorting technologies have myriad applications. Bar-coded genetic reagents that are present in image-sorted cell populations can be sequenced, which permits powerful genomewide knockdown or overexpression screens. This application expands the number of phenotypes that are amenable to screens to identify genes that underlie disease-related cell phenotypes, a development that can uncover potential therapeutic targets.

Image-based cell sorting can be used to explore the relationship between the sorted, visible cell phenotypes and other characteristics. Cell subpopulations sorted according to morphologic characteristics might subsequently be analyzed for their genome, transcriptome, epigenome, proteome, or additional morphologic properties. In addition, sorted populations can be compared according to the response to perturbations such as drug treatments.

Sorting technologies require the classification of each cell in real time, and classifying cells with complex phenotypes requires machine learning. Therefore, whether cells with complex phenotypes might be successfully sorted remains to be seen. Nevertheless, together these advancements in the process point to a future in which precision cell subpopulations might be rapidly purified and put to good use. The study was published on May 5, 2022 in the journal The New England Journal of Medicine.

Related Links:
Newcastle University 
Broad Institute 
BD Biosciences 

Gold Supplier
Immunofluorescence Analyzer
Getein 1160
Automatic Photometer
Electrolyte Analyzer
K-Lite 5 Series
Washer Dispenser

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)

Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes.... Read more


view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more


view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.